NZ732766A - Process for the preparation of a diarylthiohydantoin compound - Google Patents

Process for the preparation of a diarylthiohydantoin compound

Info

Publication number
NZ732766A
NZ732766A NZ732766A NZ73276615A NZ732766A NZ 732766 A NZ732766 A NZ 732766A NZ 732766 A NZ732766 A NZ 732766A NZ 73276615 A NZ73276615 A NZ 73276615A NZ 732766 A NZ732766 A NZ 732766A
Authority
NZ
New Zealand
Prior art keywords
preparation
diarylthiohydantoin compound
diarylthiohydantoin
compound
intermediates
Prior art date
Application number
NZ732766A
Other languages
English (en)
Inventor
Cyril Ben Haim
Andras Horvath
Johan Erwin Edmond Weerts
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of NZ732766A publication Critical patent/NZ732766A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/14—Phosphorus; Compounds thereof
    • B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
    • B01J27/198—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
NZ732766A 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound NZ732766A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094436P 2014-12-19 2014-12-19
PCT/US2015/066356 WO2016100652A2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound

Publications (1)

Publication Number Publication Date
NZ732766A true NZ732766A (en) 2023-07-28

Family

ID=55168400

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ732766A NZ732766A (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound

Country Status (34)

Country Link
US (1) US9688655B2 (enExample)
EP (4) EP3372584B9 (enExample)
JP (2) JP6681902B2 (enExample)
KR (1) KR102586059B1 (enExample)
CN (2) CN118638097A (enExample)
AR (1) AR103228A1 (enExample)
AU (1) AU2015364537B2 (enExample)
BR (1) BR112017013113B1 (enExample)
CA (1) CA2970937A1 (enExample)
CY (3) CY1121684T1 (enExample)
DK (3) DK3372584T5 (enExample)
EA (4) EA201791390A1 (enExample)
ES (3) ES2827549T3 (enExample)
HR (3) HRP20220750T1 (enExample)
HU (2) HUE052475T2 (enExample)
IL (1) IL252843B2 (enExample)
LT (3) LT3372585T (enExample)
MA (1) MA41200B1 (enExample)
MD (1) MD3233803T2 (enExample)
ME (1) ME03420B (enExample)
MX (1) MX375467B (enExample)
NZ (1) NZ732766A (enExample)
PH (1) PH12017501152B1 (enExample)
PL (3) PL3372585T3 (enExample)
PT (3) PT3233803T (enExample)
RS (3) RS58454B1 (enExample)
SG (4) SG11201704969QA (enExample)
SI (3) SI3233803T1 (enExample)
SM (3) SMT201900208T1 (enExample)
TR (1) TR201904739T4 (enExample)
TW (4) TWI753336B (enExample)
UA (1) UA123201C2 (enExample)
WO (1) WO2016100652A2 (enExample)
ZA (1) ZA201704877B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6696986B2 (ja) 2014-12-19 2020-05-20 アラゴン ファーマシューティカルズ，インコーポレイテッド ジアリールチオヒダントイン化合物の調製方法
PT3233803T (pt) * 2014-12-19 2019-05-20 Aragon Pharmaceuticals Inc Processo para a preparação de um composto diariltioidantoína
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
CN108383749B (zh) * 2018-01-30 2021-03-09 杭州科巢生物科技有限公司 阿帕鲁胺的合成方法及其中间体
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN109651256A (zh) * 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
CN110511206A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN110511207A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN113968815B (zh) * 2020-07-24 2025-11-18 苏州科伦药物研究有限公司 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法
EP4208451A1 (en) 2020-09-04 2023-07-12 Synthon B.V. Improved process for preparation of apalutamide
EP4247813A1 (en) * 2020-11-20 2023-09-27 Amgen, Inc Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3- yl)pyridof[2,3-d]pyrimidine-2,4(1h,3h)-dione
CN113292535B (zh) * 2021-06-18 2022-07-01 南京方生和医药科技有限公司 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法
CN113402466B (zh) * 2021-06-18 2022-08-16 南京方生和医药科技有限公司 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法
CN115572264B (zh) * 2021-07-06 2025-12-05 山东新时代药业有限公司 一种恩杂鲁胺的制备方法
CN115850233B (zh) * 2021-09-24 2024-12-10 南京方生和医药科技有限公司 一种阿帕鲁胺的合成方法
CN116239536A (zh) * 2021-12-08 2023-06-09 山东新时代药业有限公司 一种阿帕鲁胺中间体化合物
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
CN117645572A (zh) * 2023-11-23 2024-03-05 奥锐特药业股份有限公司 恩扎卢胺及其中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DK2656842T3 (en) * 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
GEP20135783B (en) 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
WO2011069951A1 (en) 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives
AU2011218173C1 (en) * 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
JP5718372B2 (ja) * 2010-02-24 2015-05-13 メディベイション プロステイト セラピューティクス， インコーポレイテッド ジアリールチオヒダントイン化合物およびジアリールヒダントイン化合物を合成するためのプロセス
AU2012225038B2 (en) * 2011-03-10 2016-03-10 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
HK1207560A1 (en) * 2012-03-29 2016-02-05 Sangart, Inc. Diaspirin crosslinked pegylated hemoglobin
EP3020714B1 (en) * 2013-05-29 2022-12-28 Hinova Pharmaceuticals Inc. Imidazole diketone compound and use thereof
PT3233803T (pt) * 2014-12-19 2019-05-20 Aragon Pharmaceuticals Inc Processo para a preparação de um composto diariltioidantoína

Also Published As

Publication number Publication date
SMT202200242T1 (it) 2022-07-21
KR102586059B1 (ko) 2023-10-05
ES2919951T3 (es) 2022-07-29
SI3372584T1 (sl) 2021-08-31
CN107108507B (zh) 2024-05-28
TWI703132B (zh) 2020-09-01
BR112017013113B1 (pt) 2023-11-21
DK3372584T3 (da) 2021-01-04
US9688655B2 (en) 2017-06-27
PL3233803T3 (pl) 2019-07-31
RS61060B9 (sr) 2021-07-30
WO2016100652A3 (en) 2016-08-25
SI3372585T1 (sl) 2022-08-31
AU2015364537B2 (en) 2020-10-08
CY1123611T1 (el) 2022-03-24
AR103228A1 (es) 2017-04-26
ES2827549T3 (es) 2021-05-21
MA41200A (fr) 2017-10-25
ZA201704877B (en) 2019-02-27
HRP20220750T1 (hr) 2022-09-02
RS63455B1 (sr) 2022-08-31
PT3372585T (pt) 2022-07-08
CN107108507A (zh) 2017-08-29
TW201945342A (zh) 2019-12-01
UA123201C2 (uk) 2021-03-03
JP6903785B2 (ja) 2021-07-14
RS61060B1 (sr) 2020-12-31
SG10201912805SA (en) 2020-02-27
WO2016100652A2 (en) 2016-06-23
EP3372585B1 (en) 2022-03-30
HUE042409T2 (hu) 2019-06-28
SI3233803T1 (sl) 2019-05-31
MD3233803T2 (ro) 2019-07-31
IL252843B2 (en) 2025-02-01
SMT201900208T1 (it) 2019-05-10
RS58454B1 (sr) 2019-04-30
TW201639825A (zh) 2016-11-16
EA201892485A1 (ru) 2019-07-31
PH12017501152B1 (en) 2022-04-29
PH12017501152A1 (en) 2017-11-27
PL3372584T3 (pl) 2021-07-05
TW202031639A (zh) 2020-09-01
JP2020114842A (ja) 2020-07-30
DK3372584T5 (da) 2021-05-17
MA41200B1 (fr) 2019-05-31
LT3372584T (lt) 2020-12-10
EP3372584B9 (en) 2021-03-31
DK3233803T3 (en) 2019-04-08
IL252843B1 (en) 2024-10-01
EP3372584B1 (en) 2020-09-23
CN118638097A (zh) 2024-09-13
EA201791390A1 (ru) 2017-10-31
CA2970937A1 (en) 2016-06-23
AU2015364537A1 (en) 2017-07-06
CY1125243T1 (el) 2025-03-28
MX2017008179A (es) 2017-09-18
ME03420B (me) 2020-01-20
EP3372586A1 (en) 2018-09-12
PT3233803T (pt) 2019-05-20
SMT202000618T1 (it) 2021-01-05
ES2827549T9 (es) 2021-07-02
KR20170095976A (ko) 2017-08-23
TWI683810B (zh) 2020-02-01
BR112017013113A2 (pt) 2017-12-26
LT3372585T (lt) 2022-07-11
CY1121684T1 (el) 2020-07-31
TR201904739T4 (tr) 2019-05-21
PL3372585T3 (pl) 2022-10-10
EP3372585A1 (en) 2018-09-12
DK3372585T3 (da) 2022-05-30
JP6681902B2 (ja) 2020-04-15
EA201892487A1 (ru) 2019-07-31
JP2018501237A (ja) 2018-01-18
TWI689494B (zh) 2020-04-01
TW201945343A (zh) 2019-12-01
EP3233803B1 (en) 2019-01-30
SG10201912802XA (en) 2020-02-27
LT3233803T (lt) 2019-04-10
HUE052475T2 (hu) 2021-05-28
HRP20201847T1 (hr) 2021-03-19
PT3372584T (pt) 2020-11-13
EP3372584A1 (en) 2018-09-12
MX375467B (es) 2025-03-06
US20160176845A1 (en) 2016-06-23
IL252843A0 (en) 2017-08-31
SG10201912811QA (en) 2020-02-27
EA201892486A1 (ru) 2019-07-31
EP3233803A2 (en) 2017-10-25
ES2718539T3 (es) 2019-07-02
SG11201704969QA (en) 2017-07-28
TWI753336B (zh) 2022-01-21
HRP20190540T1 (hr) 2019-06-14
HRP20201847T2 (hr) 2021-05-28

Similar Documents

Publication Publication Date Title
PH12017501152B1 (en) Process for the preparation of a diarylthiohydantoin compound
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EP3110443A4 (en) Combination method for treatment of cancer
EP4286005A3 (en) Cancer treatment
EP3119390A4 (en) Methods of treating cancer
MX2020007742A (es) Procesos para preparar fluorocetolidos.
EP3487999A4 (en) METHODS OF TREATING CANCER
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
EP3592357A4 (en) METHOD OF TREATMENT OF CANCER
MX2017002609A (es) Procedimiento mejorado para la preparacion de lacosamida y su intermediario novedoso.
NZ751032A (en) Methods for treating ovarian cancer
HK40098354A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2，3-二氢哒嗪-4-甲酰胺
HK40097687A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2，3-二氢哒嗪-4-甲酰胺
EP3125878A4 (en) Methods of treating breast cancer
HK40032887A (en) Methods of treating cancer by inhibiting setd2
HK40032563A (en) Methods of treating cancer
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
HK40016485A (en) Methods of treating cancer
HK40036029A (en) Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
AU2016902922A0 (en) Methods of Treating Cancer (I)
HK40001292A (en) A method for targeted intraprostatic administration of prx302 for treatment of prostate cancer
AU2016902923A0 (en) Methods of Treating Cancer (II)
IN2014CH02021A (enExample)
HK1227291A1 (en) Combination method for treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2024 BY CPA GLOBAL

Effective date: 20231102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251031